Abstract
Aim Quantitative and kinetic insights into drug exposure‐disease response relationship might enhance our knowledge on loss of response and support a more effective monitoring of inflammatory activity by biomarkers in patients with inflammatory bowel diseases treated with infliximab. This study aimed to derive recommendations for dose adjustment and treatment optimisation based on mechanistic characterisation of the relationship between infliximab serum concentration and C‐reactive protein (CRP) concentration. Methods Data from an investigator‐initiated trial included 121 patients with IBD during infliximab maintenance treatment. Serum concentrations of infliximab, anti‐drug antibodies (ADA), CRP, and disease‐related covariates were determined at the mid‐term and end of a dosing interval. Data were analysed using a pharmacometric nonlinear mixed‐effects modelling approach. An infliximab exposure‐CRP model was generated and applied to evaluate dosing regimens to achieve CRP remission. Results The generated quantitative model showed that infliximab has the potential to inhibit up to 72% (9% RSE) of CRP synthesis in a patient. Infliximab concentration leading to 90% of the maximum CRP synthesis inhibition was 18.4 μg/mL (43% RSE). Presence of ADA was the most influential factor on infliximab exposure. With standard dosing strategy, ≥55% of ADA+ patients experienced CRP nonremission. Shortening the dosing interval and co‐therapy with immunomodulators were found to be most beneficial to maintain CRP remission. Conclusions With the generated model we could for the first time establish a robust relationship between infliximab exposure and CRP synthesis inhibition, that could be utilized for treatment optimisation in IBD patients.

This publication has 29 references indexed in Scilit: